upgrad buy neutral littl late parti survey
upgrad share neutral buy
pt upgrad base view zbh rosa commerci
progress better expect support survey
implant user believ key question whether rosa success
sell broader recon custom base rather abl sell rosa
surgeon exist custom answer ye rosa alon
abl drive growth next month although multipl
product support improv growth rais prospect
abl return wamgr like move toward high
end wamgr potenti exceed
beyond consensu estim survey show
approach major respond rosa major
approach trial system major trial
system subsequ plan purchas process
purchas system next month alon compel enough us
expect mark improv growth sale driven outright rosa
unit sale also pull-through higher implant volum let us clear zbh
return higher top-lin growth may sequenti linear may
higher could variabl result expect
trend direct move higher
mani investor long turnaround
commentari management object measur increas
confid mani risk outlin neutral initi
diminish notabl made signific progress toward
resolut manufactur issu importantli note aao
zbh cultur made demonstr turnaround glassdoor rate
show sizabl lift employe sentiment believ trickl
better execut next month initi said
cultur chang take year month give management lot credit
turn ship around month admittedli faster expect
survey survey orthoped surgeon across countri
screen respond primari implant vendor select
primarili zimmer biomet implant user draw primarili joint
survey suggest pair trade long zbh/short fast mani
surgeon survey mako plan buy rosa
identifi respond own mako
plan supplement mako rosa
switch think site like system futur
may see competit mako placement diminish time
seem user flip rosa near-term
valuat rate buy pt base mo ep
estim risk discuss
idc btig estim compani document
million except per share amount
made signific improv turnaround busi risk tabl believ
major manufactur cultur challeng exist prior diminsh expect improv
growth profil move progress higher result wamgr see
upsid expect base market interest rosa new product launch top-lin
improv subsequ expect adj ebitda margin improv modestli result better
full commerci launch rosa knee
launch rosa spine
lap qualiti remedi effort improv inventori level
base case scenario fall midpoint guidanc
estim revenu rise report basi compar guidanc call
 adjust ep come compar guidanc
call
upsid estim could come faster expect adopt
npi reinvigor sale forc follow suppli improv addit
upsid could seen rosa system gain rapid adopt allow
implant share gain purchas account
resurfac qualiti suppli issu worsen compani sale forc
moral shrink margin combat competitor disappoint launch
rosa could contribut wors expect result
zimmer biomet diversifi
medic technolog compani
design manufactur broad
rang orthopaed reconstruct
product zimmer hold
found justin
zimmer took current
form zimmer acquir
biomet inc april today
zimmer biomet oper global
countri
employe across world
takeaway survey
screen physician primari knee implant vendor limit respond zimmer biomet user exclus
reiter goal ass zimmer biomet abil gain rosa adopt within exist custom base
current use robot system total knee arthroplasti procedur ye system mako
figur percentag respond util robot system
respond said current use form robot system perform procedur
current robot user util mako system tka procedur though sever respond indic
primarili use uka procedur tka procedur one respond indic use
navio system procedur secondari option hospit mako sever respond
indic alreadi util rosa system tka procedur util system
sever indic feel system ad practic
regard current use robot system total knee arthroplasti procedur
plan purchas robot system next month ye system pleas explain
respond indic current util robot system tka said plan
purchas system within next month major indic interest rosa
sever look mako major still felt robot system either costli prove
could provid greater clinic benefit practic want purchas system
approach zimmer biomet repres rosa robot knee system
figur respond approach repres
respond indic contact rep discuss rosa system feel strong
number rep success blanket market build interest system consist
kol call believ mani surgeon regardless prefer compel offer robot order remain
competit within respect marketplac
figur percentag respond current util robot approach rep
respond current use robot practic contact rep feel strong
result well demonstr compani success canvass doctor like
interest system
trial zimmer biomet rosa robot system
figur percentag respond trial rosa
half respond trial rosa think management would like number slightli higher
given current roll-out remain limit almost half account trial system would success view
figur percentag respond contact rep progress trial
impress number view success convers rate rep experienc among
doctor discuss system two-third doctor respond contact
rep rosa indic follow trial system feel could posit
indic appeal system demonstr zbh earli effort target potenti earli adopt limit
figur current robot user trial rosa
along line doctor current util robot trial rosa
process acquir acquir rosa robot knee system
figur percentag respond plan acquir rosa
respond indic system plan alreadi acquir rosa system
like sampl doctor like earli adopt strong result consid
penetr robot tka estim
figur percentag respond trial rosa expect purchas
one highli posit data point view two-third convers rate doctor trial rosa system
current plan purchas purchas system ultim flow
convers rate doctor approach repres actual purchas would
expect rate hold particularli approach competit account strong earli indic success
use anoth robot system zimmer biomet rosa system today total primari knee
procedur alreadi consid switch system zimmer biomet new rosa system
figur non-rosa user plan purchas
among doctor current util non-rosa robot system littl quarter current plan
ad rosa practic us indic make headway competit account though
unlik replac exist system
pleas rank order mako smith nephew navio zimmer biomet rosa follow featur pre-
oper plan featur intra-op navig soft tissu balanc cut mechan patient
specif cut user interfac softwar least favor favor
figur averag rate compar system
averag rank rel line across system slightli greater score rosa slightli wors
score navio pre-op plan intra-op navig soft tissu balanc score rate
notic better rosa pre-op plan cut score notabl lower navio
similar score rosa mako cut repres somewhat skew respons mani doctor felt
strongli prefer either way similar debat heard anecdot doctor whether
prefer haptic mechan mako note physician popul primarili zimmer implant custom
would expect rosa favor rate amongst system
show individu histogram plot system competit system
addit thought upgrad
improv compani cultur notic impact result
compar zimmer biomet glassdoor rate august initi compani rate today
mark improv employe sentiment toward compani believ translat better execut
success quarter lower spend improv turnov ultim improv oper result
figur overal compani rate employe
could wrong
weve note improv may sequenti linear segment within zimmer biomet may take
longer improv spine cmf dental lesser degre survey sampl size could prove small
reflect competit respons smith nephew may mount could sway surgeon away
rosa current street model slight regress adj ebitda margin
believ upsid number may need ultim spend higher level anticip
achiev level growth expect invest new growth area move beyond wamgr would
weigh margin diminish ep leverag
increas expect top-lin growth primarili came us knee segment
expect rosa impact model report revenu growth y/i y/i xfx put us
consensu weve also rais expect us knee growth call total report revenu
growth y/i xfx consensu year lastli y/i
consensu
zimmer biomet rate buy pt base month ep estim seen
multipl numer year consid rel valuat ihi ntm price-to-earnings basi prior
transform compani would typic trade ihi rel basi impli reason
risk rate pt includ loss market share competitor inabl remov risk relat manufactur
slower rosa commerci anticip lack consist execut goal lack margin expans
due increas invest
btig research estim compani filingsnewold changentm laboratoriesabtneutr inc baxnot dickinsonbdxnot scientificbsxbuy lifesciencesewneutr nephew adrsnnnot varneutr biometzbhbuy factset data btig estim ptpricemarket cap bev/ebitdap/ ex-amortev/salescagr
incom etot y/i sale special oper incom incom tax expens net share net incom share gross net net oper tax expens btig research estim compani report
revenu y/i btig research estim compani report
btig cover compani mention report
appendix analyst certif import disclosur
